MetaCap

Alto Neuroscience (ANRO) vs MoonLake Immunotherapeutics (MLTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alto Neuroscience (ANRO) has outperformed MoonLake Immunotherapeutics (MLTX) over the past year, gaining 91.5% versus a loss of 12.6%. Alto Neuroscience is the larger company by market cap ($1.02 billion vs $942.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANRO+91.47%MLTX-12.63%
+187%+76%-35%
Nov 21, 20251 yearNov 20, 2026
ANRO+22.56%MLTX-79.96%
+80%-10%-99%
Jan 29, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANRO versus MLTX key metrics
MetricANROMLTX
Share price$25.37$11.07
Market cap$1.02B$942.13M
1-day change-4.30%+0.36%
YTD return+42.53%-16.01%
1-year return+91.47%-12.63%
5-year return—+12.16%
EPS (TTM)$-2.32$-3.66
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-63.24M$-227.32M
52-week high$37.48$23.29
52-week low$12.51$9.46
Distance from 52-week high-32.31%-52.47%
Analyst consensusstrong_buybuy
Avg. price target upside+52.42%+173.62%
Average volume614.92K1.64M
Shares outstanding40.11M85.11M
Employees68130
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ANRO has outperformed MLTX by 104.1 percentage points over the past year.

About Alto Neuroscience

ANRO stock →

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 68 employees

About MoonLake Immunotherapeutics

MLTX stock →

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.

Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees

ANRO vs MLTX FAQ

Which is bigger, Alto Neuroscience or MoonLake Immunotherapeutics?

Alto Neuroscience (ANRO) is larger, with a market capitalization of $1.02B compared with $942.13M for MoonLake Immunotherapeutics (MLTX).

Which stock has performed better over the past year, ANRO or MLTX?

ANRO returned +91.47% over the past 12 months, compared with -12.63% for MLTX (price return, excluding dividends). Past performance does not predict future results.

Are Alto Neuroscience and MoonLake Immunotherapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons